---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019358"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:36:36.973522+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics Q1 net loss $7.2M, cash $1.4M after $6.1M offering

## Summary
- Net loss $7.2M ($0.20/share) vs $6.5M ($0.75/share) Q1 2023; R&D $2.7M, G&A $4.0M.
- Cash & restricted cash $1.4M at Mar 31, 2024, down from $2.1M at Dec 31, 2023.
- Closed public offering of 15.2M shares/warrants, gross proceeds $6.1M.
- Will present three posters at ASCO 2024 including Phase 1 update for CLD-101 in recurrent high-grade glioma.
- CEO states focus on raising additional capital and cost cutting; Phase 1 initiation with Northwestern expected Q3 2024 subject to capital.

## SEC filing metadata
- accession: 0001493152-24-019358
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315224019358/0001493152-24-019358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315224019358/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019358
- JSON: https://secwatch.observer/filing/0001493152-24-019358.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019358.txt

## Key facts
- Earnings Releases
  Calidi Biotherapeutics, Inc. reported three months ended March 31, 2024 results: net income $7.2 million, EPS $0.20 per share.
  - Period: three months ended March 31, 2024
  - Net income: $7.2 million
  - EPS: $0.20 per share
  - Result: reported results
  source text: The company reported a net loss of $7.2 million, or $0.20 per share, for the three months ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855485/000149315224019358/0001493152-24-019358-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.